SCHEMBL19229658

SCHEMBL19229658

CNC(=O)COCCOCCNC(=O)CCCCC1SCC2NC(=O)NC21

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 3/20 0.70
▸ F2 P00734 1/20 0.67
▸ PRSS1 P07477 1/20 0.67
▸ PRSS2 P07478 1/20 0.67
▸ PRSS3 P35030 1/20 0.67
▸ TPSAB1 Q15661 1/20 0.67
▸ FOLH1 Q04609 4/20 0.61
▸ TDP1 Q9NUW8 5/20 0.58
▸ HSP90AB1 P08238 1/20 0.54
▸ CA12 O43570 2/20 0.54
▸ CA1 P00915 2/20 0.54
▸ CA2 P00918 2/20 0.54
▸ CA9 Q16790 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ ABL1 P00519 1/20 0.54
▸ LMNA P02545 1/20 0.54
▸ IDE P14735 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ RIN1 Q13671 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15003104 0.93 PRSS1 (0.68) PKMF2PRSS1PRSS2PRSS3
SCHEMBL26345832 0.93 PRSS1 (0.68) PKMF2PRSS1PRSS2PRSS3
SCHEMBL20388821 0.93 PRSS1 (0.68) PKMF2PRSS1PRSS2PRSS3
SCHEMBL13223691 0.92 F2 (0.67) PKMF2PRSS1PRSS2PRSS3
SCHEMBL15216220 0.92 F2 (0.73) PKMF2PRSS1PRSS2PRSS3
SCHEMBL19017236 0.92 F2 (0.73) PKMF2PRSS1PRSS2PRSS3
SCHEMBL4968230 0.92 F2 (0.73) PKMF2PRSS1PRSS2PRSS3
SCHEMBL19751698 0.92 F2 (0.73) PKMF2PRSS1PRSS2PRSS3
SCHEMBL13328289 0.91 PKM (0.69) PKMF2PRSS1PRSS2PRSS3
SCHEMBL16602280 0.91 F2 (0.73) PKMF2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10429385-B2 Treating conditions associated with sepsis TLA TARGETED IMMUNOTHERAPIES AB (SE) 2019-10-01 — — US disclosed
EP-2718312-B1 TREATING CONDITIONS ASSOCIATED WITH SEPSIS TLA TARGETED IMMUNOTHERAPIES AB (SE) 2018-07-25 — — EP disclosed
US-20180038859-A1 TREATING CONDITIONS ASSOCIATED WITH SEPSIS TLA TARGETED IMMUNOTHERAPIES AB (SE) 2018-02-08 — — US disclosed
US-9726666-B2 Diagnosing and treating inflammatory diseases TLA TARGETED IMMUNOTHERAPIES AB (SE) 2017-08-08 — — US disclosed
Send feedback